Targeting protein homeostasis with small molecules as a strategy for the development of pan-coronavirus antiviral

Yu-Qian Mao1, Shahrzad Jahanshahi1,2, Ramy Malty1,3

  • 1Department of Biochemistry, University of Toronto, Toronto, ON, Canada.

Communications Biology
|November 7, 2024
PubMed

Insights

Researchers developed broad-spectrum antiviral therapies targeting host cell mechanisms to combat evolving coronaviruses like SARS-CoV-2. Three compounds showed efficacy against multiple strains, including delta and omicron variants, inhibiting viral replication in vitro and in organoids.

Area of Science:

  • Virology
  • Drug Discovery
  • Molecular Biology

Background:

  • The COVID-19 pandemic presents ongoing challenges due to SARS-CoV-2 evolution and new variants.
  • Viral resistance necessitates the development of novel, broad-spectrum antiviral therapies.
  • Targeting host cell mechanisms offers a strategy to overcome viral resistance.

Purpose of the Study:

  • To develop broad-spectrum pan-coronavirus antiviral therapies.
  • To identify compounds targeting host protein quality control mechanisms essential for viral replication.
  • To evaluate the efficacy of identified compounds against SARS-CoV-2 and its variants.

Main Methods:

  • Screening of an in-house compound library targeting cellular proteostasis.
  • In vitro testing of candidate compounds against multiple coronaviruses, including SARS-CoV-2.
  • Evaluation of antiviral efficacy in lung organoids and against specific SARS-CoV-2 strains (delta, omicron).
  • Development of a BSL2-level cell-integrated SARS-CoV-2 replicon for high-throughput screening.

Main Results:

  • Three compounds (cordycepin, benzothiozole analog, acyldepsipeptide analog) were identified.
  • Compounds demonstrated dose-dependent inhibition of viral replication in vitro and in lung organoids.
  • Efficacy was observed against SARS-CoV-2, including delta and omicron variants.

Conclusions:

  • Targeting host proteostasis provides a promising strategy for broad-spectrum antiviral drug development.
  • The identified compounds represent potential candidates for pan-coronavirus therapies.
  • The developed SARS-CoV-2 replicon is a valuable tool for future antiviral research.